

Appendix 8 (as submitted by the authors): Cost-Effectiveness Results for different prevalence assumptions							
		Compare to Common baseline (No Screening)					
Prevalence	Strategy	Cost	QALYs	ΔCost	ΔQALYs	ICER	Sequential ICER
0.2%	No screening	\$71,284	13.7792	-	-	-	-
	Screen & treat with PR	\$71,352	13.7803	\$68	0.0011	\$62,191	\$62,191*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$71,397	13.7818	\$113	0.0026	\$43,844	\$43,844
	Screen & treat with G1: simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	\$71,397	13.7813	\$114	0.0021	\$53,078	Dominated
	No screening	\$71,319	13.7685	-	-	-	-
0.5%	Screen & treat with PR	\$71,430	13.7713	\$112	0.0027	\$41,086	\$41,086*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$71,544	13.7750	\$225	0.0065	\$34,864	\$34,864
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	\$71,545	13.7739	\$226	0.0054	\$42,170	Dominated
	No screening	\$71,436	13.7330	-	-	-	-
	Screen & treat with PR	\$71,694	13.7411	\$258	0.0082	\$31,597	\$31,597*
1.5%	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$72,034	13.7524	\$598	0.0194	\$30,876	\$30,876
	Screen & treat with G1:simeprevir+PR G2/3: SOF/RBV G4/5/6: PR	\$72,036	13.7490	\$600	0.0161	\$37,375	Dominated
	No screening	\$71,436	13.7330	-	-	-	-
	Screen & treat with PR	\$71,694	13.7411	\$258	0.0082	\$31,597	\$31,597*
	Screen & treat with G1: IFN-Free DAA G2/3: SOF/RBV G4/5/6: PR	\$72,034	13.7524	\$598	0.0194	\$30,876	\$30,876
G1: genotype 1; G2/3: genotype 2 or 3; G4/5/6: genotype 4 or 5 or 6; PR = pegylated interferon plus ribavirin; QALY = quality-adjusted life-year; SIM = simeprevir; SOF/RBV = sofosbuvir plus ribavirin; IFN-Free DAA = interferon-free direct-acting antiviral agents; ICER = incremental cost-effectiveness ratio							

Appendix to: Wong WWL, Tu HA, Feld JJ, et al. Cost-effectiveness of screening for hepatitis C in Canada. *CMAJ* 2015. DOI:10.1503/cmaj.140711.

Copyright © 2015 The Author(s) or their employer(s).

To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca

^aExtendedly dominated = the combination of two other alternatives dominated the treatment.